Loading...

Marc Dall'Era

TitleASSOC PROF OF CLIN-HCOMP
InstitutionUniversity of California Davis
DepartmentUrology
Address4860 Y St
CA 95817
Phone(916)893-7906
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Dall'Era MA, De Vere White RW. New Insights into Ejaculatory Frequency and Prostate Cancer Risk: Association, Causation, or What Do We Have to Lose? Eur Urol. 2018 Aug 31. PMID: 30177292.
      View in: PubMed
    2. Dall'Era M, Lara PN. Editorial Comment. J Urol. 2018 Jul 18. PMID: 30030973.
      View in: PubMed
    3. Dall'Era MA, Lo MJ, Chen JY, Cress R, Hamilton AS. Reply to Radiation therapy does not increase survival in addition to standard androgen deprivation therapy for metastatic prostate cancer: An old, faded picture? Cancer. 2018 Jul 05. PMID: 29975411.
      View in: PubMed
    4. Dall'Era MA, deVere-White R, Rodriguez D, Cress R. Changing Incidence of Metastatic Prostate Cancer by Race and Age, 1988-2015. Eur Urol Focus. 2018 May 04. PMID: 29735368.
      View in: PubMed
    5. Glass AS, Dall'Era MA. Indications for and transitioning to secondary treatment while on active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):236-242. PMID: 29732282.
      View in: PubMed
    6. Dall'Era MA, Davies BJ, Eggener S. Active surveillance for prostate cancer. Transl Androl Urol. 2018 Apr; 7(2):195-196. PMID: 29732276.
      View in: PubMed
    7. Dall'Era MA, Lo MJ, Chen J, Cress R, Hamilton AS. Nine-year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer. Cancer. 2018 May 01; 124(9):1921-1928. PMID: 29499075.
      View in: PubMed
    8. Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP. Genomic Markers in Prostate Cancer Decision Making. Eur Urol. 2018 Apr; 73(4):572-582. PMID: 29129398.
      View in: PubMed
    9. Gheibi P, Zeng S, Son KJ, Vu T, Ma AH, Dall'Era MA, Yap SA, de Vere White RW, Pan CX, Revzin A. Microchamber Cultures of Bladder Cancer: A Platform for Characterizing Drug Responsiveness and Resistance in PDX and Primary Cancer Cells. Sci Rep. 2017 Sep 25; 7(1):12277. PMID: 28947782.
      View in: PubMed
    10. Yuh LM, Lara PN, Wagenaar RM, Evans CP, Dall'era MA, Cress R, Yap SA. A contemporary population-based study of testicular sex cord stromal tumours: Presentation, treatment patterns, and predictors of outcome. Can Urol Assoc J. 2017 Sep; 11(9):E344-E349. PMID: 29382456.
      View in: PubMed
    11. Glass AS, Pugashetti NB, Dall'Era MA, Evans CP, Yap SA. Utility of Anterior Zone Biopsy in Men Enrolled in Active Surveillance for Prostate Cancer. Clin Genitourin Cancer. 2017 Jul 14. PMID: 28789835.
      View in: PubMed
    12. Seiler R, Ashab HAD, Erho N, van Rhijn BWG, Winters B, Douglas J, Van Kessel KE, Fransen van de Putte EE, Sommerlad M, Wang NQ, Choeurng V, Gibb EA, Palmer-Aronsten B, Lam LL, Buerki C, Davicioni E, Sjödahl G, Kardos J, Hoadley KA, Lerner SP, McConkey DJ, Choi W, Kim WY, Kiss B, Thalmann GN, Todenhöfer T, Crabb SJ, North S, Zwarthoff EC, Boormans JL, Wright J, Dall'Era M, van der Heijden MS, Black PC. Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. Eur Urol. 2017 Oct; 72(4):544-554. PMID: 28390739.
      View in: PubMed
    13. Dall'Era M, Evans C. Genomic and Biological Markers to Select Treatment for Patients with Prostate Cancer: Choose Wisely, My Friend. J Urol. 2017 Jan; 197(1):8-9. PMID: 27746279.
      View in: PubMed
    14. Pan A, Zhang H, Li Y, Lin TY, Wang F, Lee J, Cheng M, Dall'Era M, Li T, deVere White R, Pan CX, Lam KS. Disulfide-crosslinked nanomicelles confer cancer-specific drug delivery and improve efficacy of paclitaxel in bladder cancer. Nanotechnology. 2016 Oct 21; 27(42):425103. PMID: 27640312.
      View in: PubMed
    15. Dall'Era MA. Reasons for Abandonment of Active Surveillance in Men with Prostate Cancer. J Urol. 2016 Sep; 196(3):637-8. PMID: 27316451.
      View in: PubMed
    16. Yap SA, Yuh LM, Evans CP, Dall'Era MA, Wagenaar RM, Cress R, Lara PN. Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol. 2017 Feb; 35(2):277-283. PMID: 27306686.
      View in: PubMed
    17. Chow H, Ghosh PM, deVere White R, Evans CP, Dall'Era MA, Yap SA, Li Y, Beckett LA, Lara PN, Pan CX. A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancer. Cancer. 2016 06 15; 122(12):1897-904. PMID: 27019001; PMCID: PMC4892938 [Available on 06/15/17].
    18. Belair CD, Paikari A, Moltzahn F, Shenoy A, Yau C, Dall'Era M, Simko J, Benz C, Blelloch R. DGCR8 is essential for tumor progression following PTEN loss in the prostate. EMBO Rep. 2015 Sep; 16(9):1219-32. PMID: 26206718; PMCID: PMC4576988.
    19. Dall'Era MA, Davies BJ. Clinical Case Discussion: Intermediate-risk Prostate Cancer: The Case for Active Surveillance. Eur Urol Focus. 2015 Sep; 1(2):208-209. PMID: 28723436.
      View in: PubMed
    20. Dall'Era M, Carroll P. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? J Urol. 2015 Sep; 194(3):615-6. PMID: 26079332.
      View in: PubMed
    21. Dall'Era MA. Patient and disease factors affecting the choice and adherence to active surveillance. Curr Opin Urol. 2015 May; 25(3):272-6. PMID: 25692724.
      View in: PubMed
    22. Nguyen HG, Tilki D, Dall'Era MA, Durbin-Johnson B, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Espinós EL, Mandel P, Martinez-Salamanca JI, Master VA, McKiernan JM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Rodriguez-Faba O, Russo P, Scherr DS, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Cardiopulmonary Bypass has No Significant Impact on Survival in Patients Undergoing Nephrectomy and Level III-IV Inferior Vena Cava Thrombectomy: Multi-Institutional Analysis. J Urol. 2015 Aug; 194(2):304-308. PMID: 25797392; PMCID: PMC5012645.
    23. Pugashetti N, Yap SA, Lara PN, Gandour-Edwards R, Dall'Era MA. Metastatic signet-ring cell carcinoma of the urinary bladder: A novel management approach to a rare tumour. Can Urol Assoc J. 2015 Mar-Apr; 9(3-4):E204-7. PMID: 26085880; PMCID: PMC4455640.
    24. Tomlinson B, Lin TY, Dall'Era M, Pan CX. Nanotechnology in bladder cancer: current state of development and clinical practice. Nanomedicine (Lond). 2015; 10(7):1189-201. PMID: 25929573; PMCID: PMC4562431.
    25. Tilki D, Kim SI, Hu B, Dall'Era MA, Evans CP. Ultrasensitive prostate specific antigen and its role after radical prostatectomy: a systematic review. J Urol. 2015 May; 193(5):1525-31. PMID: 25444980.
      View in: PubMed
    26. Zargar H, Espiritu PN, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Gandhi NM, Griffin J, Montgomery JS, Vasdev N, Yu EY, Youssef D, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Garcia JA, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Black PC. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur Urol. 2015 Feb; 67(2):241-9. PMID: 25257030; PMCID: PMC4840190.
    27. Tilki D, Hu B, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chandrasekar T, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Linares E, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Thieu W, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of synchronous metastasis distribution on cancer specific survival in renal cell carcinoma after radical nephrectomy with tumor thrombectomy. J Urol. 2015 Feb; 193(2):436-42. PMID: 25063493.
      View in: PubMed
    28. Wu JN, Fish KM, Evans CP, Devere White RW, Dall'Era MA. No improvement noted in overall or cause-specific survival for men presenting with metastatic prostate cancer over a 20-year period. Cancer. 2014 Mar 15; 120(6):818-23. PMID: 24258693.
      View in: PubMed
    29. Tilki D, Nguyen HG, Dall'Era MA, Bertini R, Carballido JA, Chromecki T, Ciancio G, Daneshmand S, Gontero P, Gonzalez J, Haferkamp A, Hohenfellner M, Huang WC, Koppie TM, Lorentz CA, Mandel P, Martinez-Salamanca JI, Master VA, Matloob R, McKiernan JM, Mlynarczyk CM, Montorsi F, Novara G, Pahernik S, Palou J, Pruthi RS, Ramaswamy K, Rodriguez Faba O, Russo P, Shariat SF, Spahn M, Terrone C, Vergho D, Wallen EM, Xylinas E, Zigeuner R, Libertino JA, Evans CP. Impact of histologic subtype on cancer-specific survival in patients with renal cell carcinoma and tumor thrombus. Eur Urol. 2014 Sep; 66(3):577-83. PMID: 23871402.
      View in: PubMed
    30. Dall'Era MA. The economics of active surveillance for prostate cancer. Curr Opin Urol. 2013 May; 23(3):278-82. PMID: 23449496.
      View in: PubMed
    31. Dall'Era MA, Cheng L, Pan CX. Contemporary management of muscle-invasive bladder cancer. Expert Rev Anticancer Ther. 2012 Jul; 12(7):941-50. PMID: 22845409; PMCID: PMC3494992.
    32. Dall'Era MA, Albertsen PC, Bangma C, Carroll PR, Carter HB, Cooperberg MR, Freedland SJ, Klotz LH, Parker C, Soloway MS. Active surveillance for prostate cancer: a systematic review of the literature. Eur Urol. 2012 Dec; 62(6):976-83. PMID: 22698574.
      View in: PubMed
    33. Kim S, Dall'Era MA, Evans CP. Economic analysis of active surveillance for localized prostate cancer. Curr Opin Urol. 2012 May; 22(3):247-53. PMID: 22388666.
      View in: PubMed
    34. Keegan KA, Dall'Era MA, Durbin-Johnson B, Evans CP. Active surveillance for prostate cancer compared with immediate treatment: an economic analysis. Cancer. 2012 Jul 15; 118(14):3512-8. PMID: 22180322; PMCID: PMC3698480.
    35. McGahan JP, Loh S, Fitzgerald E, Koppie T, Evans CP, Dall'Era M, Li CS. Pretreatment imaging can be used to select imaging guidance, ultrasound alone versus CT plus ultrasound, for percutaneous renal radiofrequency ablation. AJR Am J Roentgenol. 2011 Nov; 197(5):1244-50. PMID: 22021521.
      View in: PubMed
    36. Dall'Era MA, Cowan JE, Simko J, Shinohara K, Davies B, Konety BR, Meng MV, Perez N, Greene K, Carroll PR. Surgical management after active surveillance for low-risk prostate cancer: pathological outcomes compared with men undergoing immediate treatment. BJU Int. 2011 Apr; 107(8):1232-7. PMID: 20804478.
      View in: PubMed
    37. Wu JN, Dall'Era MA. Active surveillance for localized prostate cancer--current practices and recommendations. ScientificWorldJournal. 2010 Dec 14; 10:2352-61. PMID: 21170486.
      View in: PubMed
    38. Davies BJ, Smaldone MC, Sadetsky N, Dall'era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009 Jul; 182(1):112-7; discussion 117. PMID: 19447437.
      View in: PubMed
    39. Dall'Era MA, Carroll PR. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol. 2009 May; 19(3):258-62. PMID: 19295434.
      View in: PubMed
    40. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol. 2009 Apr; 181(4):1628-33; discussion 1633-4. PMID: 19233388.
      View in: PubMed
    41. Dall'Era MA, Konety BR, Cowan JE, Shinohara K, Stauf F, Cooperberg MR, Meng MV, Kane CJ, Perez N, Master VA, Carroll PR. Active surveillance for the management of prostate cancer in a contemporary cohort. Cancer. 2008 Jun 15; 112(12):2664-70. PMID: 18433013.
      View in: PubMed
    42. Dall'Era MA, Kane CJ. Watchful waiting versus active surveillance: appropriate patient selection. Curr Urol Rep. 2008 May; 9(3):211-6. PMID: 18765115.
      View in: PubMed
    43. Dall'Era MA, Cooperberg MR, Chan JM, Davies BJ, Albertsen PC, Klotz LH, Warlick CA, Holmberg L, Bailey DE, Wallace ME, Kantoff PW, Carroll PR. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer. 2008 Apr 15; 112(8):1650-9. PMID: 18306379.
      View in: PubMed
    44. Dall'Era MA, Konety BR. Active surveillance for low-risk prostate cancer: selection of patients and predictors of progression. Nat Clin Pract Urol. 2008 May; 5(5):277-83. PMID: 18285752.
      View in: PubMed